NOTE: Peripheral access inlet flow rates were used on the cTPE device, but not on the mTPE system
DISCLAIMER: This graphic is intended to be a high-level representation of an apheresis procedure and therefore does not cover all steps. For a detailed description please contact Terumo BCT.
Spectra Optia simplifies the operator’s work and makes it easy to complete procedures.
Spectra Optia provides an efficient TPE procedure time while maintaining procedural safety limits, allowing operators to maximize the time with patients and improve the patient experience.
Flow rates up to 142 mL/min can be used while maintaining procedure efficiency.4 For smaller patients, a flow rate of 5 mL/min or less can be used. This adapts to the operator’s needs and the patient’s condition.
When tailoring a procedure for each patient, operators appreciate the flexibility of the multiple venous access options that can be used with the Spectra Optia system, including:
The reliability of Spectra Optia offers peace of mind for physicians and operators alike.
View Webinar Online
See how David Ward, MD, Medical Director, Apheresis Program, University of California San Diego (UCSD), La Jolla, California uses cTPE on Spectra Optia.
MANUALS, INSTRUCTIONS FOR USE OR ADDITIONAL INQUIRIES.
1Timing study based on internal laboratory time studies using highly trained operators. Time is approximate and results may vary depending on operator experience. Data on file.
2Kes P, et al. A randomized crossover study comparing membrane and centrifugal therapeutic plasma exchange procedures. Transfusion. 2016;56(12):2065-3072.
3Data on file; encompasses data from more than 40,000 procedures.
4Procedures can be defined as being efficient in terms of the following:
Puppe B, Kingdon EJ. Membrane and centrifugal therapeutic plasma exchange: practical difficulties in anticoagulating the extracorporeal circuit. Clin Kidney J. 2014;7(2):201-205.
Hafer C, Golla P, Gericke M, et al. Membrane versus centrifuge-based therapeutic plasma exchange: a randomized prospective crossover study. Intl Urol and Nephrol. 2016;48(1):133-138.
Products available in select markets.